{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T17:17:33Z","timestamp":1792343853208,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40263-023-01026-3","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T20:23:50Z","timestamp":1691612630000},"page":"715-723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study"],"prefix":"10.1007","volume":"37","author":[{"given":"Meredith","family":"Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan K.","family":"Al Jurdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Pat","family":"Petrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Borentain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Jing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Turkoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianne","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"1026_CR1","doi-asserted-by":"publisher","unstructured":"Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2):20m13699. https:\/\/doi.org\/10.4088\/JCP.20m13699.","DOI":"10.4088\/JCP.20m13699"},{"key":"1026_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/NDT.S198774","volume":"16","author":"D Voineskos","year":"2020","unstructured":"Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221\u201334. https:\/\/doi.org\/10.2147\/NDT.S198774.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"8","key":"1026_CR3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.cpr.2007.02.005","volume":"27","author":"SL Burcusa","year":"2007","unstructured":"Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007;27(8):959\u201385. https:\/\/doi.org\/10.1016\/j.cpr.2007.02.005.","journal-title":"Clin Psychol Rev"},{"key":"1026_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/PPA.S29716","volume":"6","author":"KS Al-Harbi","year":"2012","unstructured":"Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369\u201388. https:\/\/doi.org\/10.2147\/PPA.S29716.","journal-title":"Patient Prefer Adherence"},{"key":"1026_CR5","unstructured":"Gaynes BN, Asher G, Gartlehner G, Hoffman V, Green J, Boland E, et al. Definition of Treatment-Resistant Depression in the Medicare Population. Rockville: Agency for Healthcare Research and Quality (US); 2018."},{"issue":"15","key":"1026_CR6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jpsychires.2010.03.006","volume":"44","author":"M Riedel","year":"2010","unstructured":"Riedel M, Moller HJ, Obermeier M, Schennach-Wolff R, Bauer M, Adli M, et al. Response and remission criteria in major depression\u2014a validation of current practice. J Psychiatr Res. 2010;44(15):1063\u20138. https:\/\/doi.org\/10.1016\/j.jpsychires.2010.03.006.","journal-title":"J Psychiatr Res"},{"issue":"4","key":"1026_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.31887\/DCNS.2008.10.4\/jmendlewicz","volume":"10","author":"J Mendlewicz","year":"2008","unstructured":"Mendlewicz J. Towards achieving remission in the treatment of depression. Dialogues Clin Neurosci. 2008;10(4):371\u20135. https:\/\/doi.org\/10.31887\/DCNS.2008.10.4\/jmendlewicz.","journal-title":"Dialogues Clin Neurosci"},{"issue":"9","key":"1026_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiat. 2019;76(9):893\u2013903. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1189.","journal-title":"JAMA Psychiat"},{"key":"1026_CR9","unstructured":"SPRAVATO\u00ae (esketamine) nasal spray, CIII [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 07\/2020."},{"issue":"1","key":"1026_CR10","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12888-021-03538-y","volume":"21","author":"N Takahashi","year":"2021","unstructured":"Takahashi N, Yamada A, Shiraishi A, Shimizu H, Goto R, Tominaga Y. Efficacy and safety of fixed doses of intranasal esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. BMC Psychiatry. 2021;21(1):526. https:\/\/doi.org\/10.1186\/s12888-021-03538-y.","journal-title":"BMC Psychiatry"},{"issue":"319","key":"1026_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","volume":"15","author":"G Martinotti","year":"2022","unstructured":"Martinotti G, Vita A, Fagiolini A, Maina G, Bertolino A, Dell\u2019Osso B, et al. Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study). J Affect Disord. 2022;15(319):646\u201354. https:\/\/doi.org\/10.1016\/j.jad.2022.09.043.","journal-title":"J Affect Disord"},{"issue":"18","key":"1026_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/cer-2022-0149","volume":"11","author":"M Brendle","year":"2022","unstructured":"Brendle M, Ahuja S, Valle MD, Moore C, Thielking P, Malone DC, et al. Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study. J Comp Eff Res. 2022;11(18):1323\u201336. https:\/\/doi.org\/10.2217\/cer-2022-0149.","journal-title":"J Comp Eff Res."},{"key":"1026_CR13","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891","author":"E Wajs","year":"2020","unstructured":"Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020. https:\/\/doi.org\/10.4088\/JCP.19m12891.","journal-title":"J Clin Psychiatry"},{"key":"1026_CR14","unstructured":"Zaki N, Fu D, Daly E, Kevo S, Lopena O, Turkoz I. Long-term efficacy of esketamine nasal spray in adults with treatment-resistant depression: a subgroup analysis of the ongoing SUSTAIN-3 study. Neuroscience Education Institute (NEI) Congress; 2021 November 4\u20137, 2021; Colorado Springs, CO; 2021."},{"key":"1026_CR15","unstructured":"Zaki N, Fu D, Daly E, Kevo S, Reilly K, Turkoz I, et al. Long-Term Safety of Esketamine Nasal Spray in Adults With Treatment-Resistant Depression: A Subgroup Analysis of the SUSTAIN-3 Study. Neuroscience Education Institute (NEI) Congress; 2021 November 4\u20137, 2021; Colorado Springs, CO; 2021."},{"key":"1026_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01577-5","author":"N Zaki","year":"2023","unstructured":"Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, et al. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology. 2023. https:\/\/doi.org\/10.1038\/s41386-023-01577-5.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1026_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","volume":"192","author":"JB Williams","year":"2008","unstructured":"Williams JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008;192(1):52\u20138. https:\/\/doi.org\/10.1192\/bjp.bp.106.032532.","journal-title":"Br J Psychiatry"},{"issue":"18","key":"1026_CR18","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","volume":"282","author":"RL Spitzer","year":"1999","unstructured":"Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282(18):1737\u201344. https:\/\/doi.org\/10.1001\/jama.282.18.1737.","journal-title":"JAMA"},{"issue":"3","key":"1026_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/YIC.0b013e32832a8eb2","volume":"24","author":"SA Montgomery","year":"2009","unstructured":"Montgomery SA, M\u00f6ller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol. 2009;24(3):111\u20138. https:\/\/doi.org\/10.1097\/YIC.0b013e32832a8eb2.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"1026_CR20","first-page":"122","volume":"31","author":"SH Kennedy","year":"2006","unstructured":"Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci. 2006;31(2):122\u201331.","journal-title":"J Psychiatry Neurosci"},{"issue":"4","key":"1026_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1176\/appi.ps.201900295","volume":"71","author":"RY Coley","year":"2020","unstructured":"Coley RY, Boggs JM, Beck A, Hartzler AL, Simon GE. Defining success in measurement-based care for depression: a comparison of common metrics. Psychiatr Serv. 2020;71(4):312\u20138. https:\/\/doi.org\/10.1176\/appi.ps.201900295.","journal-title":"Psychiatr Serv"},{"issue":"5","key":"1026_CR22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.genhosppsych.2015.05.009","volume":"37","author":"SM Schueller","year":"2015","unstructured":"Schueller SM, Kwasny MJ, Dear BF, Titov N, Mohr DC. Cut points on the Patient Health Questionnaire (PHQ-9) that predict response to cognitive-behavioral treatments for depression. Gen Hosp Psychiatry. 2015;37(5):470\u20135. https:\/\/doi.org\/10.1016\/j.genhosppsych.2015.05.009.","journal-title":"Gen Hosp Psychiatry"},{"key":"1026_CR23","unstructured":"National Committee for Quality Assurance. HEDIS depression measures for electronic clinical data. 2022 January 8, 2022 [cited 2022 01\/18\/2022]."},{"issue":"2","key":"1026_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4088\/JCP.16m10641","volume":"78","author":"M Zimmerman","year":"2017","unstructured":"Zimmerman M, Walsh E, Friedman M, Boerescu DA, Attiullah N. Identifying remission from depression on 3 self-report scales. J Clin Psychiatry. 2017;78(2):177\u201383. https:\/\/doi.org\/10.4088\/JCP.16m10641.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1026_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/YIC.0000000000000010","volume":"29","author":"MY Alam","year":"2014","unstructured":"Alam MY, Jacobsen PL, Chen Y, Serenko M, Mahableshwarkar AR. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2014;29(1):36\u201344. https:\/\/doi.org\/10.1097\/YIC.0000000000000010.","journal-title":"Int Clin Psychopharmacol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01026-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01026-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01026-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T12:29:28Z","timestamp":1692361768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01026-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1026"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01026-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"2 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was supported by Janssen Scientific Affairs, LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Samuel Wilkinson discloses receiving contract research funding from Janssen, Oui Therapeutics, and Sage Therapeutics for the conduct of clinical trials (administered through Yale University); he also discloses receiving consulting fees from Janssen, Oui Therapeutics, and Sage Therapeutics. Meredith Castro, Mary Pat Petrillo, Brianne Brown, and Patricia Cabrera are employees of Janssen Scientific Affairs, LLC, and hold stock in Johnson & Johnson, Inc. Naim Zaki, Stephane Borentain, Dong Jing Fu, and Ibrahim Turkoz are employees of Janssen Research & Development, LLC, and hold stock in Johnson & Johnson, Inc. Rayan Al Jurdi receives research funding from Janssen Pharmaceuticals, Inc. and Neurolief, Inc. and also serves on the Treatment Resistant Depression (TRD) Speaker Bureau, which is financially supported by Janssen Pharmaceuticals, Inc. Liping Sun is an employee of Cytel, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study (ClinicalTrials.gov identifier: NCT02782104) was approved by Independent Ethics Committees or Institutional Review Boards. This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients signed informed consent for participation in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at\u00a0. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at\u00a0.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: SW, MC, SB, DJF, IT. Methodology: SW, MC, SB, DJF, IT, LS, BB. Software: IT, LS. Validation: IT, LS. Formal analysis: NZ, IT, LS. Investigation: RAJ, MC, DJF. Resources\/funding acquisition: MC. Data curation: MC, IT. Writing, reviewing, and editing: SW, RAJ, MC, MPP, NZ, SB, DJF, IT, LS, BB, PC. Visualization: MC, IT. Supervision\/project administration: MC. All authors contributed to drafting several versions of the manuscript and revised it critically for important intellectual content, have read and approved the final submitted manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}